Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Tryptophan Res
2013 Jan 01;6:1-6. doi: 10.4137/IJTR.S11206.
Show Gene links
Show Anatomy links
Transport of Kynurenic Acid by Rat Organic Anion Transporters rOAT1 and rOAT3: Species Difference between Human and Rat in OAT1.
Uwai Y
,
Hara H
,
Iwamoto K
.
???displayArticle.abstract???
A tryptophan catabolite, kynurenic acid, is involved in schizophrenia and uremia; there is little information on the mechanism of its disposition. Recently, our laboratory showed that kynurenic acid is a good substrate of human organic anion transporters hOAT1 and hOAT3. In this study, we performed uptake experiment using Xenopus laevis oocytes to characterize the transport of kynurenic acid by rat homologs of the transporters, rOAT1, and rOAT3. These transporters stimulated the uptake of kynurenic acid into oocytes, and transport by rOAT3 was marked. The Km values of the transport were estimated to be 8.46 μM for rOAT1 and 4.81 μM for rOAT3, and these values are comparable to their human homologs. The transport activity of kynurenic acid by rOAT1 was about one quarter of that of p-aminohippurate, although they were at the similar levels in hOAT1. A comparative experiment with hOAT1 was added in this study, showing that uptake amounts of kynurenic acid by hOAT1-expressing oocytes were 4 times greater than rOAT1-expressing oocytes. rOAT3 transported kynurenic acid as efficiently as estrone sulfate; this phenomenon was also observed in hOAT3. In conclusion, transport of kynurenic acid by rOAT1 and rOAT3 was shown. The characteristics of rOAT3 were similar to hOAT3, but low transport activity of kynurenic acid by rOAT1 was exhibited compared with hOAT1.
Figure 1. Time-dependent uptake of kynurenic acid by rOAT1 and rOAT3.Notes: Oocytes injected with water (open circle), rOAT1 cRNA (closed circle), or rOAT3 cRNA (open triangle) were incubated with 20 nM [3H] kynurenic acid for the indicated periods. The uptake amounts of [3H] kynurenic acid in each oocyte were determined. Each point represents the mean ± S.E.M. of 29 to 30 oocytes from 3 experiments. When an error bar is not shown, it is smaller than the symbol.
Figure 2. Concentration-dependent uptake of kynurenic acid by rOAT1 (A) and rOAT3 (B). (A) Oocytes injected with rOAT1 cRNA were incubated with [3H]kynurenic acid at various concentrations for 2 hours. rOAT1-mediated uptake of [3H]kynurenic acid was determined by subtracting its uptake amount in water-injected oocytes from that in oocytes injected with rOAT1 cRNA. (B) Oocytes injected with rOAT3 cRNA were incubated with [3H]kynurenic acid at various concentrations for 1 hour.Notes: rOAT3-mediated uptake of [3H]kynurenic acid was determined by subtracting its uptake amount in water-injected oocytes from that in oocytes injected with rOAT3 cRNA. Each point represents the mean ± S.E.M. of 27 to 30 oocytes from 3 experiments. When an error bar is not shown, it is smaller than the symbol.
Figure 3. Uptake of p-aminohippurate, aminopterin and kynurenic acid by hOAT1 and rOAT1.Notes: Oocytes injected with water (open column), hOAT1 cRNA (hatched column) or rOAT1 cRNA (closed column) were incubated with 221 nM [3H]p-aminohippurate, 28.5 nM [3H]aminopterin or 20 nM [3H] kynurenic acid for 1 hr. The uptake amounts of the radiolabeled compounds in each oocyte were determined and divided by their concentrations in uptake buffer. Each column represents the mean ± S.E.M. of 26 to 30 oocytes from 3 experiments. ***P < 0.001, significantly different; *P < 0.05, significantly different.
Adler,
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia.
1999, Pubmed
Adler,
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia.
1999,
Pubmed
Erhardt,
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.
2001,
Pubmed
Goralski,
In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport.
1999,
Pubmed
Hasegawa,
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions.
2002,
Pubmed
Hosoyamada,
Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney.
1999,
Pubmed
,
Xenbase
Javitt,
Recent advances in the phencyclidine model of schizophrenia.
1991,
Pubmed
Kikuchi,
Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier.
2003,
Pubmed
Kikuchi,
Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier.
2004,
Pubmed
Kusuhara,
In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney.
2009,
Pubmed
Miller,
The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations.
1992,
Pubmed
Miyazaki,
The multispecific organic anion transporter family: properties and pharmacological significance.
2004,
Pubmed
Mori,
Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.
2003,
Pubmed
,
Xenbase
Moroni,
Presence of kynurenic acid in the mammalian brain.
1988,
Pubmed
Nilsson,
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia.
2005,
Pubmed
Ohtsuki,
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
2002,
Pubmed
,
Xenbase
Pawlak,
Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.
2001,
Pubmed
Schwarcz,
Increased cortical kynurenate content in schizophrenia.
2001,
Pubmed
Schwarcz,
Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
2002,
Pubmed
Stone,
Neuropharmacology of quinolinic and kynurenic acids.
1993,
Pubmed
Swan,
Liquid-chromatographic study of fluorescent materials in uremic fluids.
1983,
Pubmed
Uwai,
Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate.
2010,
Pubmed
,
Xenbase
Uwai,
Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3.
2012,
Pubmed
,
Xenbase
Vanholder,
Review on uremic toxins: classification, concentration, and interindividual variability.
2003,
Pubmed
